Display options
Cite
Saciuk Y, Kertes J, Mandel M, et al. Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. Prev Med. 2021;155:106947doi: 10.1016/j.ypmed.2021.106947.
Saciuk, Y., Kertes, J., Mandel, M., Hemo, B., Shamir Stein, N., & Ekka Zohar, A. (2021). Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. Preventive medicine, 155106947. https://doi.org/10.1016/j.ypmed.2021.106947
Saciuk, Yaki, et al. "Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel." Preventive medicine vol. 155 (2021): 106947. doi: https://doi.org/10.1016/j.ypmed.2021.106947
Saciuk Y, Kertes J, Mandel M, Hemo B, Shamir Stein N, Ekka Zohar A. Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. Prev Med. 2021 Dec 30;155:106947. doi: 10.1016/j.ypmed.2021.106947. Epub 2021 Dec 30. PMID: 34974072; PMCID: PMC8717697.
Copy Download .nbib Format: NLM
Share it on

Prev Med. 2021 Dec 30;155:106947. doi: 10.1016/j.ypmed.2021.106947. Epub 2021 Dec 30.

Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel.

Preventive medicine

Yaki Saciuk, Jennifer Kertes, Micha Mandel, Beatriz Hemo, Naama Shamir Stein, Anat Ekka Zohar

Affiliations

  1. Dept. Health Evaluation & Research, Division of Data & Digital Health, Maccabi HealthCare Services, Rehov HaMered 27, Tel Aviv 68125, Israel.
  2. Dept. Health Evaluation & Research, Division of Data & Digital Health, Maccabi HealthCare Services, Rehov HaMered 27, Tel Aviv 68125, Israel. Electronic address: [email protected].
  3. Statistics Dept, Hebrew university of Jerusalem, Mt Scopus Campus, Har Hatsofim, Jerusalem, Israel.
  4. Division of Data & Digital Health, Maccabi HealthCare Services, Rehov HaMered 27, Tel Aviv 68125, Israel. Electronic address: [email protected].

PMID: 34974072 PMCID: PMC8717697 DOI: 10.1016/j.ypmed.2021.106947

Abstract

Development of an effective vaccine against Covid-19 is crucial to reducing infection. mRNA BNT162b2, developed and manufactured by Pfizer-BioNTech, was one of the first FDA-approved vaccinations reporting high efficacy (95%) and minimal side effects. Evaluating effectiveness of BNT162b2 in a general population has been made possible after the implementation of a nation-wide vaccination program in Israel. This retrospective cohort study was carried out in Maccabi HealthCare services, Israel among 1.6 million members aged 16 and over. The population was divided into those who were at least seven days post- second vaccination and those who had not been vaccinated. Number of days till the end of the study or Covid-19 infection, Covid-19-related hospitalization and mortality was calculated for each participant between 18.1.2021 to 25.4.2021. Participants who had reached day eight after second vaccination during the study period could contribute days to both groups. Vaccine efficacy (VE) was calculated using a conditional Poisson model, controlling for age group, gender, hypertension, diabetes and obesity, fitted within clusters defined by geographical statistical area and calendar week. BNT162b2 was found effective for the total population group for infection, hospitalization and mortality, with adjusted VE of 93·0% (CI:92·6-93·4%), 93·4% (CI:91·9-94·7%) and 91·1% (CI:86·5-94·1%) respectively. VE for infection was lower for participants aged 75 and over, and for those with hypertension, diabetes and obesity. This study strengthens the evidence that the Pfizer-BioNTech vaccination is effective in preventing infection, hospitalization and mortality.

Copyright © 2022 Elsevier Inc. All rights reserved.

Keywords: Covid-19; Pfizer-BioNTech vaccine; mRNA BNT162b2; vaccine effectiveness

Publication Types